CHLOE, 26
LIVING WITH MODERATE-TO-SEVERE AD
SINCE EARLY CHILDHOOD
Real patient being treated with DUPIXENT
Individual results may vary

SIENNA, 4
STORY INSPIRED BY REAL PATIENT
Not an actual patient
Individual results may vary

Change Their
Story Together
By partnering with a specialist

DUPIXENT is the first and only biologic approved
for the treatment of patients as young as 6 months of age with uncontrolled moderate-to-severe atopic dermatitis1

Explore the data

US.DUP.23.11.0074

HELP CHANGE
THEIR STORY

Discover how DUPIXENT may help and hear real provider and patient experiences

IDENTIFY APPROPRIATE PATIENTS

Appropriate patients may benefit by seeing a dermatologist or allergist

When topical Rx therapies are not enough, patients aged 6 months and older with moderate-to-severe disease may be appropriate for DUPIXENT. Consider a referral if they:

  • Have tried a variety of topical prescription therapies for moderate-to-severe atopic dermatitis and are still uncontrolled1
  • Suffer from inadequate control of pruritus1
  • Have ≥10% of their body covered with lesions and/or may involve problem areas, such as the face, hands, and feet1
  • Have moderate-to-severe erythema and moderate-to-severe papulation/
    infiltration (defined in clinical trials as an IGA score of 3 or 4)1,2
    IGA, Investigator's Global Assessment.
Identify appropriate patients to refer

PARTNER WITH A SPECIALIST

Find a DERMATOLOGIST or ALLERGIST for your appropriate patients trapped in flare, treat, repeat cycles

Use the Healthgrades® tool to find and partner with a nearby eczema specialist.

ABOUT DUPIXENT

DUPIXENT is the first biologic that specifically targets a source of underlying inflammation to proactively treat atopic dermatitis1,3

Atopic dermatitis is a chronic, systemic disease driven in part by persistent underlying type 2 inflammation4

  • Even when patients are not in a flare, they
    continue to have underlying inflammation3
  • Systemic treatment may be needed to help
    manage this disease1,5

WATCH HOW
DUPIXENT WORKS

Change their story by partnering with a specialist. DUPIXENT has demonstrated itch relief and skin clearance1

DUPIXENT has proven itch relief and skin clearance in patients 6+ months of age
with uncontrolled
moderate-to-severe atopic dermatitis1

Itch reduction1

Skin clearance1

DUPIXENT has a
demonstrated long-term
safety profile
across
patients 6+ months of age1

Demonstrated safety profile
through 52 weeks1

Most common adverse reactions

The most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.1

Trial Designs and Results

Important Considerations

NO BOXED WARNING1

SELECT IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information.



Other Attributes
of DUPIXENT

DUPIXENT is not an immunosuppressant
or a steroid1

No requirement for initial lab testing
or ongoing lab monitoring, according
to the Prescribing Information1

Real-world Experience

6 years on the market

since initial FDA
approval in atopic
dermatitis1,a

aFDA approved for uncontrolled moderate-to-severe AD since 2017 for adults, 2019 for adolescents (aged 12-17 years), 2020 for children (aged 6-11 years), and 2022 for infants to preschoolers (aged 6 months to 5 years).

WATCH VIDEOS ABOUT DUPIXENT

FAQs

Questions about DUPIXENT?

Below are the answers to some of the most frequently asked questions about DUPIXENT.

DUPIXENT is a biologic therapy that inhibits IL-4 and IL-13 signaling, two of the sources of type 2 inflammation. It is not an immunosuppressant or a steroid.1

The mechanism of dupilumab action has not been definitively established.

When topical Rx therapies aren't enough, DUPIXENT is the first and only biologic approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood (6+ months of age).1

DISCOVER HOW
DUPIXENT WORKS

DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6+ months of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Patients may be appropriate for DUPIXENT if they:

  • Have tried a variety of topical Rx therapies and are still uncontrolled1
  • Suffer from inadequate control of pruritus1
  • Have ≥10% of their body covered with lesions and/or may involve problem areas such as the face, hands, and feet1
  • Have moderate-to-severe erythema and moderate-to-severe papulation/infiltration (Investigator's Global Assessment [IGA] score of 3=moderate or 4=severe)1,2
Learn how to identify appropriate patients

DUPIXENT is typically prescribed by a specialist, such as a dermatologist or allergist. If you have a patient aged 6+ months with uncontrolled moderate-to-severe atopic dermatitis who you think might be appropriate for DUPIXENT, consider referring them to an eczema specialist.1

For help finding a specialist, use the Healthgrades tool.

Sanofi US and Regeneron do not endorse or recommend any particular physician, and search results do not include a comprehensive list of doctors in your area.

A specialist can confirm which patients 6+ months of age with uncontrolled moderate-to-severe atopic dermatitis may need a different approach, and prescribe a biologic like DUPIXENT—the first and only biologic approved from infancy to adulthood.1

Specialist referral can occur at any point in the clinical management of uncontrolled moderate-to-severe atopic dermatitis (6+ months).

Uncontrolled moderate-to-severe atopic dermatitis is a chronic, systemic disease that for many patients will be a lifelong condition, one that may necessitate continuous treatment. We don't know which patients may outgrow their condition, and in the meantime, those with uncontrolled disease despite TCS use may need continuous therapy to adequately control their chronic itch and skin lesions.9,11

Find a specialist near you

The most common adverse reactions (incidence ≥1%) in patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.1

See results with DUPIXENT

The safety of DUPIXENT was assessed both as monotherapy and in combination with TCS in adult patients with moderate-to-severe atopic dermatitis; as monotherapy in adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis; in combination with TCS in children 6 to 11 years with severe atopic dermatitis; and in combination with TCS in infants to preschoolers 6 months to 5 years of age with moderate-to-severe atopic dermatitis. The safety profile through Week 16 in each pediatric age group was similar to that of adults with atopic dermatitis.

In an open-label extension study, the safety profile through Week 52 in each pediatric age group was consistent with that of adults with atopic dermatitis. Hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) was reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.1

See the safety profile

DUPIXENT is an injectable medicine that is administered by subcutaneous injection. DUPIXENT is intended for use under the guidance of a healthcare provider. The DUPIXENT pre-filled pen is for use in adult and pediatric patients aged 2 years and older. The DUPIXENT pre-filled syringe is for use in adult and pediatric patients aged 6 months and older. A caregiver or patient 12 years of age and older may inject DUPIXENT using the pre-filled syringe or pre-filled pen. In pediatric patients 12 to 17 years of age, it is recommended that DUPIXENT be administered under the supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.1

EXPLORE DOSAGE AND ADMINISTRATION

99% of commercial patients (6+ months of age) nationally are covered for DUPIXENT.2,a 91% of commercial patient lives have to fail only 1 or 2 prescription topical treatments.2,a

aMMIT Analysis, September 2023.   Learn more about coverage

For patients with a valid prescription for DUPIXENT, support is available through the DUPIXENT MyWay® patient support program. Patients who enroll can receive:

  • Research and explanation of their insurance benefits
  • Ways to help with the out-of-pocket cost of DUPIXENT
  • Explanation of how to properly store DUPIXENT when they receive their shipment
  • Connection with a Nurse Educator to provide supplemental injection training—in person, virtually, or over the phone
  • A needle disposing kit or sharps container
  • Refill and injection reminders
Learn more about
DUPIXENT MyWay®
EXPLORE PATIENT SUPPORT

DUPIXENT MyWay® helps ensure patients have access to DUPIXENT and are provided with assistance in navigating the insurance process

  • 99% of commercial patients (6+ months of age) nationally are covered for DUPIXENT.2,a 91% of commercial patient lives have to fail only 1 or 2 prescription topical treatments.2,a

aMMIT Analysis, September 2023.

LEARN MORE ABOUT ACCESS

Important Safety
Information and Indications

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Conjunctivitis and Keratitis: Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT versus placebo, with conjunctivitis being the most frequently reported eye disorder. Conjunctivitis also occurred more frequently in chronic rhinosinusitis with nasal polyposis subjects and prurigo nodularis subjects who received DUPIXENT compared to those who received placebo. Conjunctivitis and keratitis have been reported with DUPIXENT in postmarketing settings, predominantly in AD patients. Some patients reported visual disturbances (e.g., blurred vision) associated with conjunctivitis or keratitis. Advise patients or their caregivers to report new onset or worsening eye symptoms to their healthcare provider. Consider ophthalmological examination for patients who develop conjunctivitis that does not resolve following standard treatment or signs and symptoms suggestive of keratitis, as appropriate.

Eosinophilic Conditions: Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA), conditions which are often treated with systemic corticosteroid therapy. These events may be associated with the reduction of oral corticosteroid therapy. Healthcare providers should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients with eosinophilia. Cases of eosinophilic pneumonia were reported in adult subjects who participated in the asthma development program and cases of vasculitis consistent with EGPA have been reported with DUPIXENT in adult subjects who participated in the asthma development program as well as in adult subjects with co-morbid asthma in the CRSwNP development program. A causal association between DUPIXENT and these conditions has not been established.

Acute Asthma Symptoms or Deteriorating Disease: Do not use DUPIXENT to treat acute asthma symptoms, acute exacerbations, acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of DUPIXENT.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-morbid Asthma: Advise patients with co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Arthralgia: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Advise patients to report new onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves. Helminth infections (5 cases of enterobiasis and 1 case of ascariasis) were reported in pediatric patients 6 to 11 years old in the pediatric asthma development program.

Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT.

ADVERSE REACTIONS:

  • Atopic Dermatitis: The most common adverse reactions (incidence ≥1%) in patients are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The safety profile in pediatric patients through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT ± TCS in pediatric patients observed through Week 52 was consistent with that seen in adults with atopic dermatitis, with hand-foot-and-mouth disease and skin papilloma (incidence ≥2%) reported in patients 6 months to 5 years of age. These cases did not lead to study drug discontinuation.
  • Asthma: The most common adverse reactions (incidence ≥1%) are injection site reactions, oropharyngeal pain, and eosinophilia.
  • Chronic Rhinosinusitis with Nasal Polyposis: The most common adverse reactions (incidence ≥1%) are injection site reactions, eosinophilia, insomnia, toothache, gastritis, arthralgia, and conjunctivitis.
  • Eosinophilic Esophagitis: The most common adverse reactions (incidence ≥2%) are injection site reactions, upper respiratory tract infections, arthralgia, and herpes viral infections.
  • Prurigo Nodularis: The most common adverse reactions (incidence ≥2%) are nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to https://mothertobaby.org/ongoing-study/dupixent/. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
  • Lactation: There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full Prescribing Information.

Indications

Atopic Dermatitis: DUPIXENT is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Asthma: DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP): DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled CRSwNP.

Eosinophilic Esophagitis: DUPIXENT is indicated for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).

Prurigo Nodularis: DUPIXENT is indicated for the treatment of adult patients with prurigo nodularis (PN).

References:

  1. DUPIXENT Prescribing Information.
  2. Data on file, Regeneron Pharmaceuticals, Inc.
  3. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
  4. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657.
  5. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2.
  6. Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022;400(10356):908-919.
  7. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
  8. Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282-1293.
  9. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
  10. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44-56.
  11. Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226-232.